481 results on '"Algeciras‐Schimnich, Alicia"'
Search Results
2. Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force
3. Longitudinal monitoring of enzyme-linked immunosorbent assay for NC16A-BP180 or BP230 antibodies as a biomarker of disease activity in pemphigoid: A systematic review
4. Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice
5. Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays
6. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
7. Plasma biomarkers for prediction of Alzheimer’s disease neuropathologic change
8. Author Correction: Performance of plasma phosphorylated tau 181 and 217 in the community
9. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders
10. Performance of plasma phosphorylated tau 181 and 217 in the community
11. Proteomic Identification of Plasma Proteins Associated with Future Dementia Development
12. Effect of cerebrovascular risk factors on the prediction of Alzheimer’s disease neuropathologic change using plasma biomarkers (N4.003)
13. Results from a Phase 2 Clinical Trial of Repeated Intrathecal Autologous Adipose-derived MSCs in ALS (S5.004)
14. Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer's disease
15. CSF phosphorylated tau as an indicator of subsequent tau accumulation
16. Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study
17. Development of a PTHrP chemiluminescent immunoassay to assess humoral hypercalcemia of malignancy
18. Comparison of intact protein and digested peptide techniques for high throughput proteotyping of ApoE
19. Blood tests for Alzheimer's disease: The impact of disease prevalence on test performance
20. Importance of cerebrospinal fluid (CSF) collection protocol for the accurate diagnosis of Alzheimer's disease when using CSF biomarkers
21. Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals
22. Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology
23. False Positives in Thyroglobulin Determinations Due to the Presence of Heterophile Antibodies: An Underrecognized and Consequential Clinical Problem
24. Evaluation of sporadic bovine alkaline phosphatase interference in the Beckman Access unconjugated estriol (uE3) assay affecting maternal serum screening results
25. Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies.
26. Bewildered by Biotin
27. Identification of Necessary Plasma Biomarkers for Prediction of Alzheimer’s Disease Neuropathologic Change
28. Trajectories of plasma biomarkers of Alzheimer’s disease and neurodegeneration in the general population
29. Plasma biomarkers of Alzheimer’s disease in a biracial, community‐based sample
30. Plasma biomarkers of Alzheimer´s disease in the continuum of dementia with Lewy bodies
31. Non‐imaging measures to predict variability in white matter changes relevant to VCID
32. Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
33. Vascular risk, gait, behavioral, and plasma indicators of VCID
34. Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays
35. Evaluation of Siltuximab and Tocilizumab Analytical Interference on Interleukin 6 Measurements
36. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes
37. Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)2D and normal FGF7 concentrations characterize patients with CKD
38. Procalcitonin: Are We Ready for Clinical Use?
39. Vascular risk, gait, behavioral, and plasma indicators of VCID.
40. Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET.
41. Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort
42. Plasma‐derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community‐based study
43. Corrigendum to “Plasma neurofilament light chain (NfL) reference interval determination in an age-stratified cognitively unimpaired cohort” [Clin. Chim. Acta 535 (2022) 153-156]
44. Two CD95 Tumor Classes with Different Sensitivities to Antitumor Drugs
45. Evaluation of the CLSI EP26-A protocol for detection of reagent lot-to-lot differences
46. Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis.
47. CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics
48. Identification, Measurement, and Assessment of the Clinical Utility of Human Pancreatic Polypeptide by Liquid Chromatography–Tandem Mass Spectrometry
49. Predicting amyloid PET and tau PET stages with plasma biomarkers
50. Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer’s Disease and Vascular Pathology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.